Compare Johnson & Johnson (JNJ) vs Live Nation Entertainment, Inc. (LYV) Price & Performance

Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.

JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.

Live Nation (LYV) trades at $177.83, down 1.33% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported $25.20B revenue for 2025 with a slim 0.33% net margin, while recent earnings misses have pressured sentiment. Strong cash flow from operations of $1.40B supports ongoing investments in live events, with analyst consensus overwhelmingly bullish at 88.6% buy ratings.

Outlook remains positive due to resilient live event demand and projected 2026 revenue growth to $25.60B, though risks include high valuation multiples (P/E 117.5), recent earnings misses, and sensitivity to consumer discretionary spending. The consensus price target of $201.50 suggests 13% upside potential from current levels.